Antiviral Drugs Market: Current Analysis and Forecast (2021-2027)

Antiviral Drugs Market: Current Analysis and Forecast (2021-2027)

The global Antiviral Drugs market is expected to witness robust growth mainly due to the spreaders of viral infection with increasing chronic diseases like HIV, herpes, hepatitis, and influenza which also leads to attack immune system cause fever, headache, especially among the middle-aged population. HIV is an immunodeficient disease that targets the body’s immune system in three phase and causes AIDS (acquired immunodeficiency syndrome). Despite the existence of medications that can control HIV and even reduce viral transmission, HIV is still a leading cause of death and a health threat to millions worldwide. In 2019, approximately 690,000 people died of AIDS-related causes and 1.7 million people were newly infected with HIV. Many therapies are available for the treatment of HIV, including topical, systemic, and injectable modalities.

Based on disease type, the Antiviral Drugs Market is segmented into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors and others. In 2020, Reverse Transcriptase Inhibitors category dominated the market and is expected to maintain its dominance throughout the forecast period. This is mainly due to the rising geriatric population coupled with unhealthy lifestyle and hormonal imbalance across the globe.

Based on application, the market is bifurcated into HIV, herpes, hepatitis, and influenza. Among these, HIV category accounted for the major share in the global Antiviral Drugs. Major pharma companies in the market are continuously working on developing and conduction clinical trials of new drugs for the treatment of HIV. For instance, in 2019, the U.S. government announced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2030. The initiative seeks to reduce HIV infections and improve the diagnosis and treatment rate. Thus, market is expected to witness significant growth during the forecast period.

Based on distribution channel, the market is bifurcated into hospitals and clinics, drug stores and retail pharmacies, and online pharmacies. In 2020, hospitals and clinics category accounted for the majority share in the global market. This can be ascribed to the fact that hospitals and clinics are first step in disease diagnosis. Thus, when a diagnosis is accurate and made in a timely manner, a patient has the best opportunity for a positive health outcome because clinical decision making will be tailored to a correct understanding of the patient's health problem.

For a better understanding of the market, the report is analyzed based on different regions including North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Spain, Rest of Europe); Asia-Pacific (China, India, Japan, South Korea, Rest of Asia-Pacific); and Rest of World.

Some of the major players operating in the market include AbbVie Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc. Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited.